{
  "extraction_metadata": {
    "timestamp": "2025-10-04T14:37:52.807716",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to deterioration, time to progression of the tumor, intraoperative complications, mortality, morbidity",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, adverse events (general)",
      "ChunksUsed": 12,
      "ContextTokens": 2963
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, tumour response (mRECIST), intraoperative complications, mortality, morbidity, disease progression, time to deterioration, time to progression of the tumor, adverse events, neurotoxicity",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "long-term survival, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, recurrence, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2057
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications",
      "ChunksUsed": 12,
      "ContextTokens": 2639
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (biopsy), diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound), pathological examination, immunohistochemistry markers, genetic tests, molecular classification",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates (RECIST criteria), diarrhoea, fatigue, nausea, neutropenia, adverse events (CTCAE v5.0), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 3575
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "",
      "Error": "Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4.1 in organization org-qjlBCLCPywLruyzWD3MengrF on tokens per min (TPM): Limit 30000, Used 25813, Requested 4217. Please try again in 60ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "ChunksUsed": 12,
      "ContextTokens": 3023
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), local tumour control, success rate (downstaging/bridging), complications, distress, physical complaints, psychosocial complaints, early detection of local recurrence, early detection of de novo tumor, alpha-fetoprotein (AFP) monitoring, pulmonary metastasis, burden of disease",
      "ChunksUsed": 12,
      "ContextTokens": 2916
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "tumour response (RECIST criteria), tumour response (mRECIST), tumour response (multiphase computed tomography with contrast), tumour response (magnetic resonance imaging with contrast), perioperative mortality, adverse events, progression, time to progression, effectiveness of ablation (multiphase computed tomography with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (ultrasonography not appropriate), bridging therapy benefit, overall survival",
      "ChunksUsed": 12,
      "ContextTokens": 2703
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, quality of life, tumour response, resectability, varicose vein bleeding, ascites, hepatic encephalopathy (grade > 1 on the New Haven criteria), portal hypertension",
      "ChunksUsed": 12,
      "ContextTokens": 2045
    }
  }
}